Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide Comment

被引：0
|
作者：
Ritzel, Robert [1 ]
机构：
[1] Stadt Klinikum Munchen, Klin Endokrinol Diabetol & Angiol, Munchen Klin Schwabing & Bogenhausen, Munich, Germany
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2019年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [21] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [22] ORAL SEMAGLUTIDE: THE INNOVATION IN TYPE 2 DIABETES MANAGEMENT
    Shestakova, Marina V.
    Shamkhalova, Minara Sh.
    Galstyan, Gagik R.
    Ruyatkina, Ludmila A.
    Suplotova, Ludmila A.
    [J]. DIABETES MELLITUS, 2021, 24 (03): : 273 - 281
  • [23] Effect of semaglutide on alanine aminotransferase in subjects with type 2 diabetes and high cardiovascular risk
    Sanyal, Arun J.
    Hansen, Morten
    Linder, Martin
    Newsome, Philip N.
    [J]. HEPATOLOGY, 2017, 66 : 1175A - 1175A
  • [24] Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes"
    Cheema, Muhammad Rafay Shahzad
    Kumar, Satesh
    [J]. ACTA DIABETOLOGICA, 2023, 60 (05) : 715 - 716
  • [25] Response to "Effects of Semaglutide on Cardiovascular Risk Factors and Eating Behaviors in Type 2 Diabetes"
    Venjhraj, F. N. U.
    Kumar, Mukesh
    Ram, Meva
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (10)
  • [26] Response to “Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes”
    Muhammad Rafay Shahzad Cheema
    Satesh Kumar
    [J]. Acta Diabetologica, 2023, 60 : 715 - 716
  • [27] Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
    Husain, Mansoor
    Bain, Stephen C.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Sorrig, Rasmus
    Treppendahl, Marianne B.
    Vilsboll, Tina
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 442 - 451
  • [28] Multifactorial risk reduction with oral semaglutide vs comparators in the treatment of type 2 diabetes
    Aroda, V. R.
    Eliasson, J.
    Malling, B.
    Meier, J. J.
    Nielsen, L. L.
    Vilsboll, T.
    Khunti, K.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S312 - S313
  • [29] Reduction of cardiovascular risk - A new approach in the treatment of type-2 diabetes
    Standl, E
    [J]. MEDIZINISCHE KLINIK, 2003, 98 : 1 - 1
  • [30] Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management
    Raparelli, Valeria
    Morano, Susanna
    Franconi, Flavia
    Lenzi, Andrea
    Basili, Stefania
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1471 - 1476
12345